Cost-Effectiveness of Nurse-Led Disease Management for Heart Failure in an Ethnically Diverse Urban Community
Authors:
- 21 October 2008
- journal article
- research article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 149 (8) , 540-548
Abstract
Randomized, controlled trials have shown that nurse-led disease management for patients with heart failure can reduce hospitalizations. Less is known about the cost-effectiveness of these interventions. To estimate the cost-effectiveness of a nurse-led disease management intervention over 12 months, implemented in a randomized, controlled effectiveness trial. Cost-effectiveness analysis conducted alongside a randomized trial. Medical costs from administrative records, and self-reported quality of life and nonmedical costs from patient surveys. Patients with systolic dysfunction recruited from ambulatory clinics in Harlem, New York. 12 months. Societal and payer. 12-month program that involved 1 face-to-face encounter with a nurse and regular telephone follow-up. Quality of life as measured by the Health Utilities Index Mark 3 and EuroQol-5D and cost-effectiveness as measured by the incremental cost-effectiveness ratio (ICER). Costs and quality of life were higher in the nurse-managed group than the usual care group. The ICERs over 12 months were $17 543 per EuroQol-5D–based quality-adjusted life-year (QALY) and $15 169 per Health Utilities Index Mark 3–based QALY (in 2001 U.S. dollars). From a payer perspective, the ICER ranged from $3673 to $4495 per QALY. Applying national prices in place of New York City prices yielded a societal ICER of $13 460 to $15 556 per QALY. Cost-effectiveness acceptability curves suggest that the intervention was most likely cost-effective for patients with less severe (New York Heart Association classes I to II) heart failure. The trial was conducted in an ethnically diverse, inner-city neighborhood; thus, results may not be generalizable to other communities. Over 12 months, the nurse-led disease management program was a reasonably cost-effective way to reduce the burden of heart failure in this community.Keywords
This publication has 25 references indexed in Scilit:
- Heart Disease and Stroke Statistics—2007 UpdateCirculation, 2007
- Estimating mean QALYs in trial‐based cost‐effectiveness analysis: the importance of controlling for baseline utilityHealth Economics, 2004
- Cost‐effectiveness acceptability curves – facts, fallacies and frequently asked questionsHealth Economics, 2004
- Transitional Care of Older Adults Hospitalized with Heart Failure: A Randomized, Controlled TrialJournal of the American Geriatrics Society, 2004
- Predicting EuroQoL EQ-5D Preference Scores from the SF-12 Health Survey in a Nationally Representative SampleMedical Decision Making, 2004
- Mapping the SF-12 to Preference-Based InstrumentsMedical Care, 2003
- Trends In Avoidable Hospitalizations, 1980–1998Health Affairs, 2001
- A Comprehensive League Table of Cost-Utility Ratios and a Sub-table of "Panel-worthy" StudiesMedical Decision Making, 2000
- Willingness to Pay for a Quality-adjusted Life YearMedical Decision Making, 2000
- Cost-effectiveness Analysis in Clinical PracticeArchives of internal medicine (1960), 1999